Rodin Therapeutics

OverviewSuggest Edit

Rodin Therapeutics is a biotechnology company discovering and developing first in class therapeutics for neurological disorders. The Company applies unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes.
TypePrivate
Founded2013
HQCambridge, US
Websiterodintherapeutics.com

Latest Updates

Employees (est.) (Oct 2019)17(+7%)

Key People/Management at Rodin Therapeutics

Adam Rosenberg

Adam Rosenberg

CEO

Rodin Therapeutics Office Locations

Rodin Therapeutics has an office in Cambridge
Cambridge, US (HQ)
300 Tech Square, 300 Technology Square
Show all (1)

Rodin Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Rodin Therapeutics total Funding

$57.2 m

Rodin Therapeutics latest funding size

$27 m

Time since last funding

2 years ago

Rodin Therapeutics investors

Rodin Therapeutics's latest funding round in October 2017 was reported to be $27 m. In total, Rodin Therapeutics has raised $57.2 m
Show all financial metrics

Rodin Therapeutics Online and Social Media Presence

Embed Graph

Rodin Therapeutics News and Updates

Rodin Therapeutics Expands Leadership Team, Adding Extensive Experience in Clinical and Business Development

PRESS RELEASE: Rodin Therapeutics today announced the appointments of three senior executives with extensive experience in clinical and business development as well as a senior scientific advisor to focus on pipeline strategy. With their strong backgrounds...

Rodin Therapeutics Blogs

Rodin Therapeutics Announces Publication of Paper Demonstrating Pro-Synaptic Effects of CoREST-Selective Inhibitors

CAMBRIDGE, Mass. – December 5, 2018 – Rodin Therapeutics today announced the publication of a scientific paper demonstrating the efficacy of novel compounds which selectively inhibit the HDAC-CoREST complex. In preclinical models, the compounds promote synaptic growth and function while minimizing t…

Rodin Therapeutics Launches Clinical Trial of Neuroimaging Tool for Measurement of Synaptic Density

CAMBRIDGE, Mass., October 18, 2018 — Rodin Therapeutics today announced the launch of a clinical trial to assess the performance of a new PET ligand that can measure synaptic density in the living brain. Insights from the study will guide Rodin’s upcoming Phase 1b trial of a novel therapeutic compou…

Rodin Therapeutics Frequently Asked Questions

  • When was Rodin Therapeutics founded?

    Rodin Therapeutics was founded in 2013.

  • Who are Rodin Therapeutics key executives?

    Rodin Therapeutics's key executives are Adam Rosenberg.

  • How many employees does Rodin Therapeutics have?

    Rodin Therapeutics has 17 employees.

  • Who are Rodin Therapeutics competitors?

    Competitors of Rodin Therapeutics include Inovio Pharmaceuticals, MyoKardia and Reata Pharmaceuticals.

  • Where is Rodin Therapeutics headquarters?

    Rodin Therapeutics headquarters is located at 300 Tech Square, 300 Technology Square, Cambridge.

  • Where are Rodin Therapeutics offices?

    Rodin Therapeutics has an office in Cambridge.

  • How many offices does Rodin Therapeutics have?

    Rodin Therapeutics has 1 office.